Why TransMedics Stock Fell — and Why Analysts Aren’t Worried
TransMedics shares dropped after FDA clearance of a rival liver perfusion system, but TD Cowen says the selloff is overdone and sees no real competitive threat.
/ 907 items
#Healthcare↓
Johnson & Johnson Q4 Earnings Beat, But Stock Falls on Stelara
Johnson & Johnson reports Q4 earnings of $2.46/share, beating estimates with 9.1% sales growth to $24.6B, but stock falls 3% on Stelara patent loss concerns.
Lisata Therapeutics Acquired by Kuva Labs for $4/Share
Kuva Labs to acquire Lisata at $4/share plus $2 in contingent payments—an 85% premium. Deal expected to close before Feb 27, 2026.
BofA Starts Coverage of Inhibikase Therapeutics with Buy Rating
BofA gives Inhibikase Therapeutics (IKT) a Buy rating with $6 target, citing strong data, regulatory support, and promising leukemia therapy for PAH.
RBC Capital Turns Bullish on Biohaven: Big Upgrade and Higher Price Target
RBC Capital upgrades Biohaven to Outperform, raises price target to $22, and highlights improving data, lower risk, and strong 2026 catalysts.
BofA Upgrades Apellis as Empaveli Shows Strong Early Momentum
Bank of America upgraded Apellis to Buy, citing undervalued shares and strong early uptake of Empaveli in rare kidney diseases.